Core Biogenesis and Nucleus Biologics announce strategic collaboration for manufacturing and distribution of cost effective and sustainable recombinant proteins

  • Post author:
  • Post category:uncategorized

In a joint effort to provide lower cost and more defined reagents and media to the cell and gene therapy market, Nucleus Biologics, The Cell Performance Company™, a leading provider of…

Continue ReadingCore Biogenesis and Nucleus Biologics announce strategic collaboration for manufacturing and distribution of cost effective and sustainable recombinant proteins

Plaquetec and the Babraham Institute collaborate on phenotypic screen of coronary artery blood

  • Post author:
  • Post category:uncategorized

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), based at the Babraham Research Campus, and the Flow Cytometry Facility at the Babraham Institute today announced a…

Continue ReadingPlaquetec and the Babraham Institute collaborate on phenotypic screen of coronary artery blood

Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases

  • Post author:
  • Post category:uncategorized

Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx), companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, today announced their merger to…

Continue ReadingCalluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases